F026 Granulomatous Disorders of the Adult Skin
DESCRIPTION
Come to the best session at the Academy! Learn about all the things you hope you don't have to see/diagnose/manage (or if you love them, come hang out with your fellows!)
Granulomatous disorders represent a unique group of diseases, both noninfectious and infectious, that require clinical pathological correlation combined with an understanding of underlying systemic disease and appropriate pharmacologic interventions. Dermatologists need to be able to differentiate granuloma annulare, sarcoidosis, necrobiosis lipoidica, reactive granulomatous dermatitis and drug-induced granulomatous reactions, NXG, Rubella-granulomas, and more! Learn how to evaluate patients for underlying systemic diseases, and treat them with appropriate therapeutic agents.
LEARNING OBJECTIVES
Review granulomatous diseases of the skin, providing a framework to recognize different clinical presentations, interpret dermatopathology, evaluate patients for systemic disease involvement, and develop an approach to treatment
Identify characteristics of and differentiate between Granuloma Annulare, Necrobiosis Lipoidica, Sarcoidosis, Reactive Granulomatous Diseases (IGD/PNGD), Necrobiotic Xanthogranuloma, Cutaneous Crohn Disease, and more
Discuss translational advances, personalized medicine, novel therapeutics, and targeted approaches to treatments
SCHEDULE
1:00 PM
Introduction
Misha Rosenbach, MD, FAAD
1:05 PM
Granuloma Annulare
Bridget Shields, MD, FAAD
1:15 PM
Necrobiosis Lipoidica
Claire Hannah, MD, FAAD
1:25 PM
Sarcoidosis
Sotonye Imadojemu, MD, FAAD
1:35 PM
Necrobiotic Xanthogranuloma
Sung Kyung Cho, MD
1:45 PM
Cutaneous Crohns, Granulomatous Cheilitis, OFG
Alexandra Coromilas, MD, FAAD
1:55 PM
JAKi's and Emerging Therapeutics
William Damsky, PhD, MD, FAAD
2:05 PM
Reactive Granulomatous Dermatitis
Avrom Caplan, MD, FAAD
2:15 PM
Rubella virus associated Granulomatous Dermatitis
Karolyn Wanat, MD, FAAD
2:25 PM
Granulomatous Mastitis
Mariam Laura Alam, MD, FAAD
2:35 PM
Granulomatous Drug Reactions
Emily R. Nadelmann, MD, FAAD
DIRECTOR
Misha Rosenbach, MD, FAAD
University of Pennsylvania
SPEAKERS
Mariam Laura Alam, MD, FAAD
Avrom Caplan, MD, FAAD
Sung Kyung Cho, MD
Alexandra Coromilas, MD, FAAD
William Damsky, PhD, MD, FAAD
Claire Hannah, MD, FAAD
Sotonye Imadojemu, MD, FAAD
Emily R. Nadelmann, MD, FAAD
Bridget Shields, MD, FAAD
Karolyn Wanat, MD, FAAD
DISCLOSURES
Mariam Laura Alam, MD, FAAD
No financial relationships exist with ineligible companies.
Avrom Caplan, MD, FAAD
Novartis – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Advisory Board(Fees), Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);
Alexandra Coromilas, MD, FAAD
No financial relationships exist with ineligible companies.
William Damsky, PhD, MD, FAAD
AbbVie – Investigator(Fees); Advanced Cell Diagnostics, Inc. – Investigator(Equipment); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); CSL Behring – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Consultant(Fees); Epiarx Diagnostics – Consultant (1099 relationship)(Fees); Fresenius Kabi – Consultant (1099 relationship)(Fees); Incite – Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); MilliporeSigma – Other(Patent royalties or other compensation for Intellectual Property Rights); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); TWi Biote – Consultant (1099 relationship)(Fees); TWi Biotechnology, Inc. – Consultant(Fees), Consultant (1099 relationship)(Fees), Investigator(Fees);
Claire Hannah, MD, FAAD
Priovant Therapeutics – Investigator(Grants/Research Funding);
Sotonye Imadojemu, MD, FAAD
No financial relationships exist with ineligible companies.
Emily R. Nadelmann, MD, FAAD
No financial relationships exist with ineligible companies.
Misha Rosenbach, MD, FAAD
Google Ventures – Consultant (1099 relationship)(Honoraria); J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); OpenEvidence – Advisory Board(Other Financial Benefit); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding);
Bridget Shields, MD, FAAD
Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria); UpToDate, Inc – Other(Honoraria);
Karolyn Wanat, MD, FAAD
No financial relationships exist with ineligible companies.